Eprinomectin

Parasitic infection is a core long-term health risk in the livestock breeding field. It will not only lead to the decline of growth performance and impaired reproductive capacity of livestock and poultry, but also cause large-scale death in severe cases, resulting in significant economic losses to the breeding industry. Eprinomectin, as an avermectin-class semi-synthetic anti-parasitic active pharmaceutical ingredient (API), belongs to macrolide anthelmintics. It binds to the glutamate-gated chloride channels of parasite neurons and muscle cells with high affinity, increases the permeability of cell membranes to chloride ions, and leads to the neuromuscular paralysis and death of parasites. It has the characteristics of broad-spectrum anthelmintic activity and long-acting effect. This drug is mainly used to treat nematode infections, sarcoptic mange, psoroptic mange and other ectoparasitic diseases in domestic livestock, and is a commonly used anthelmintic API in large-scale breeding scenarios for cattle, sheep, pigs and other livestock.

At present, the global market size of veterinary anti-parasitic drugs has exceeded 8.5 billion US dollars, among which avermectin-class drugs account for nearly 40%. With higher safety and longer duration of action than ivermectin, eprinomectin has maintained a compound annual growth rate of around 7.2% in the past three years. In terms of the competitive landscape, the original research product accounts for about 22% of the high-end market, while the API production capacity is mainly concentrated in China and India. Relying on cost advantages and process optimization, domestic enterprises have become the main suppliers of eprinomectin API in the world, with their export volume accounting for more than 60% of the total global trade volume.

The original research enterprise of eprinomectin is Merck Sharp & Dohme (MSD), and the original brand name is Eprinex. Its core compound patent expired in the United States in 2003, and the core patent in the European Union also expired in 2004. The main dosage form approved by the original research is pour-on, with a common specification of 5mg/ml. The original pour-on has been included in the FDA Reference Listed Drug (RLD) catalog, and no original formulation has been marketed in China yet. As of October 2024, eprinomectin APIs from 3 domestic enterprises have obtained Class A status through CDE registration, which can be used for associated formulation review, and registration applications from a number of other enterprises are still under review. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for eprinomectin API. Most of the products are in stock, and orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, which fully meet the reference standard use needs of enterprises in the whole process from process research and development to quality research and declaration and registration.